The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation
Open accessAbstract
Background: The Crohn’s & Colitis Foundation’s Cost of Inflammatory Bowel Disease (IBD) Care Initiative seeks to quantify the wide-ranging health care costs affecting patients living with IBD. We aimed to (1) describe the annualized direct and indirect costs of care for patients with Crohn’s disease (CD) or ulcerative colitis (UC), (2) determine the longitudinal drivers of these costs, and (3) characterize the cost of care for newly diagnosed patients. Methods: We analyzed the Optum Research Database from the years 2007 to 2016, representing commercially insured and Medicare Advantage–insured patients in the United States. Inclusion for the study was limited to those who had continuous enrollment with medical and pharmacy benefit coverage for at least 24 months (12 months before through 12 months after the index date of diagnosis). The value of patient time spent on health care was calculated as number of workplace hours lost due to health care encounters multiplied by the patients’ estimated average wage derived from the Bureau of Labor Statistics. Comparisons between IBD patients and non-IBD patients were analyzed based on demographics, health plan type, and length of follow-up. We used generalized linear models to estimate the association between total annual costs and various patient variables. Results: There were 52,782 IBD patients (29,062 UC; 23,720 CD) included in the analysis (54.1% females). On a per-annual basis, patients with IBD incurred a greater than 3-fold higher direct cost of care compared with non-IBD controls ($22,987 vs $6956 per-member per-year paid claims) and more than twice the out-of-pocket costs ($2213 vs $979 per-year reported costs), with all-cause IBD costs rising after 2013. Patients with IBD also experienced significantly higher costs associated with time spent on health care as compared with controls. The burden of costs was most notable in the first year after initial IBD diagnosis (mean = $26,555). The study identified several key drivers of cost for IBD patients: treatment with specific therapeutics (biologics, opioids, or steroids); ED use; and health care services associated with relapsing disease, anemia, or mental health comorbidity. Conclusion: The costs of care for IBD have increased in the last 5 years and are driven by specific therapeutics and disease features. In addition, compared with non-IBD controls, IBD patients are increasingly incurring higher costs associated with health care utilization, out-of-pocket expenditures, and workplace productivity losses. There is a pressing need for cost-effective strategies to address these burdens on patients and families affected by IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
The global burden of IBD: from 2015 to 2025
Kaplan, G. G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.150 · Cited by 2,639
Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults
Kappelman, M. D., Rifas–Shiman, S. L., Porter, C. Q., Ollendorf, D. A., Sandler, R. S., Galanko, J. A., & Finkelstein, J. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.012 · Cited by 634
Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years — United States, 2015
Dahlhamer, J. M., Zammitti, E. P., Ward, B. W., Wheaton, A. G., & Croft, J. B. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6542a3 · Cited by 622
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016) · JAMA · doi:10.1001/jama.2016.11237 · Cited by 592
van der Valk, M. E., Mangen, M.-J. J., Leenders, M., Dijkstra, G., van Bodegraven, A. A., Fidder, H. H., de Jong, D. J., Pierik, M., van der Woude, C. J., Romberg-Camps, M. J. L., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-303376 · Cited by 500
Market share and costs of biologic therapies for inflammatory bowel disease in the USA
Yu, H., MacIsaac, D., Wong, J. J., Sellers, Z. M., Wren, A. A., Bensen, R., Kin, C., & Park, K. T. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14430 · Cited by 180
Self-citationThe Direct and Indirect Cost Burden of Crohn's Disease and Ulcerative Colitis
Gibson, T. B., Ng, E., Ozminkowski, R. J., Wang, S., Burton, W. N., Goetzel, R. Z., & Maclean, R. (2008) · Journal of Occupational & Environmental Medicine · doi:10.1097/jom.0b013e318181b8ca · Cited by 167
The Cost of Hospitalization in Crohn's Disease
Cohen, R. D., Larson, L. R., Roth, J., Becker, R. V., & Mummert, L. H. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01779.x · Cited by 147
Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States
Park, K. T., & Bass, D. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21488 · Cited by 132
Self-citation
Cited by
Ananthakrishnan, A. N., Kaplan, G. G., & Ng, S. C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.028 · Cited by 279
Agrawal, M., Spencer, E. A., Colombel, J.-F., & Ungaro, R. C. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.063 · Cited by 261
The effect of psychotherapy on quality of life in IBD Patients: A systematic review
Paulides, E., Boukema, I., van der Woude, C. J., & de Boer, N. K. H. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa144 · Cited by 47
“In addition, a recent study from Park et al 53 also appointed mental health comorbidities as a crucial key cost driver and showed that costs of patients with mental health diagnoses were almost twice as high as those of patients without mental health issues.”
BackgroundRiggott, C., Fairbrass, K. M., Black, C. J., Gracie, D. J., & Ford, A. C. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17735 · Cited by 14
Metadata
- Authors
- Park, K. T., Ehrlich, O. G., Allen, J. I., Meadows, P., Szigethy, E. M., Henrichsen, K., Kim, S. C., Lawton, R. C., Murphy, S. M., Regueiro, M., Rubin, D. T., Engel-Nitz, N. M., & Heller, C. A.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-21
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1078-0998 (ISSN-L)
- 1536-4844
- OpenAlex
- W2946537104
- Cited by
- 431
- References
- 17
- FWCI
- 27.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation. https://app.cochat.ai/papers/10.1093/ibd/izz104
- The paper
- Park, K. T., Ehrlich, O. G., Allen, J. I., Meadows, P., Szigethy, E. M., Henrichsen, K., Kim, S. C., Lawton, R. C., Murphy, S. M., Regueiro, M., Rubin, D. T., Engel-Nitz, N. M., & Heller, C. A. (2020). The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izz104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.